David Happel's Insider Trades & SAST Disclosures
David Happel's most recent trade in Sagimet Biosciences Inc - Ordinary Shares - Class A was a trade of 472,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 6, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David Happel.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Sagimet Biosciences Inc - ... | David Happel | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 472,000 | 472,000 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | David Happel | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 116,000 | 755,200 | - | 0 | Series A Common Stock | |
| Sagimet Biosciences Inc - ... | David Happel | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 5.27 per share. | 26 Mar 2024 | 12,100 | 639,200 | - | 5.3 | 63,731 | Series A Common Stock |
| Sagimet Biosciences Inc - ... | Happel David | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 4.10 per share. | 07 Dec 2023 | 1,600 | 627,100 | - | 4.1 | 6,560 | Series A Common Stock |
| Sagimet Biosciences Inc - ... | David Happel | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 1,011,826 | 1,011,826 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | David Happel | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 1,011,826 | 0 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges